Align Technology (ALGN) – Investment Analysts’ Weekly Ratings Changes

A number of research firms have changed their ratings and price targets for Align Technology (NASDAQ: ALGN):

• 2/14/2025 – Align Technology is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $255.00 price target on the stock.
• 2/6/2025 – Align Technology had its price target lowered by analysts at Morgan Stanley from $280.00 to $272.00. They now have an “overweight” rating on the stock.
• 2/6/2025 – Align Technology had its price target lowered by analysts at Piper Sandler from $275.00 to $270.00. They now have an “overweight” rating on the stock.
• 2/6/2025 – Align Technology had its price target raised by analysts at Evercore ISI from $240.00 to $260.00. They now have an “outperform” rating on the stock.
• 2/6/2025 – Align Technology had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 1/23/2025 – Align Technology had its price target lowered by analysts at Jefferies Financial Group Inc. from $285.00 to $260.00. They now have a “buy” rating on the stock.
• 1/6/2025 – Align Technology was upgraded by analysts at Leerink Partnrs from a “hold” rating to a “strong-buy” rating.
• 1/6/2025 – Align Technology was upgraded by analysts at Leerink Partners from a “market perform” rating to an “outperform” rating. They now have a $280.00 price target on the stock, up previously from $235.00.

Align Technology Trading Up 0.2 %

ALGN stock traded up $0.29 during trading on Monday, reaching $190.72. The stock had a trading volume of 1,027,838 shares, compared to its average volume of 821,802. The stock’s 50 day moving average is $215.05 and its two-hundred day moving average is $224.43. The firm has a market cap of $14.24 billion, a PE ratio of 34.00, a PEG ratio of 2.33 and a beta of 1.67. Align Technology, Inc. has a 52 week low of $185.20 and a 52 week high of $335.40.

Align Technology (NASDAQ:ALGN) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.96 EPS for the quarter, missing analysts’ consensus estimates of $2.43 by ($0.47). Align Technology had a net margin of 10.54% and a return on equity of 13.84%. On average, research analysts anticipate that Align Technology, Inc. will post 7.98 EPS for the current year.

Hedge Funds Weigh In On Align Technology

A number of institutional investors and hedge funds have recently made changes to their positions in the business. True Wealth Design LLC grew its position in Align Technology by 10,700.0% in the third quarter. True Wealth Design LLC now owns 108 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 107 shares in the last quarter. Picton Mahoney Asset Management lifted its stake in shares of Align Technology by 69.9% in the 4th quarter. Picton Mahoney Asset Management now owns 141 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 58 shares during the last quarter. GKV Capital Management Co. Inc. purchased a new position in shares of Align Technology in the 4th quarter worth approximately $31,000. Neo Ivy Capital Management bought a new position in shares of Align Technology during the 3rd quarter valued at approximately $32,000. Finally, Aster Capital Management DIFC Ltd bought a new stake in Align Technology in the fourth quarter worth $35,000. 88.43% of the stock is owned by hedge funds and other institutional investors.

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.